Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Pfe crawled time : 13:30 save search
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
fda approval for hiv living
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
Published: 2024-01-08 (Crawled : 13:30) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.71%
H: 0.36%
C: 0.11%
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 0.0%
H: 8.15%
C: 1.48%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.37%
H: 1.09%
C: 0.75%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.19%
H: 0.34%
C: 0.21%
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.32%
H: 0.26%
C: -0.18%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.28%
H: 0.99%
C: 0.93%
HUTCHMED announces retirement of CEO and appointment of new CEO
Published: 2022-03-03 (Crawled : 13:30) - chi-med.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 3.11%
H: 0.0%
C: 0.0%
ces new ceo ceo
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Published: 2021-12-10 (Crawled : 13:30) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
ARVN | $34.3 2.54% 2.48% 800K
|
Health Technology
|
| O: -2.1%
H: 0.0%
C: 0.0%
arv-471 protac cancer breast cancer her2- her2
NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
Published: 2021-11-30 (Crawled : 13:30) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -4.99%
H: 0.0%
C: 0.0%
treatment renal trial therapeutics collaboration cell carcinoma
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
Published: 2021-11-19 (Crawled : 13:30) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: -2.67%
H: 0.45%
C: 0.45%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 3.28%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
covid fda vaccine merge order emergency use authorization
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.